Takeda Pharmaceutical (TAK) Gross Margin (2017 - 2026)

Takeda Pharmaceutical's Gross Margin history runs 10 years deep, the most recent figure standing at 62.93% for Q1 2026.

• On a quarterly basis, Gross Margin fell 503.0% year-over-year to 62.93% in Q1 2026; TTM through Mar 2026 was 65.17%, a 63.0% decrease from a year earlier, with the FY2026 full-year figure at 65.12%, up 4720.0% from the prior year.
• Gross Margin steadied at 62.93% in Q1 2026 per TAK's latest filing, from 62.93% in the prior quarter.
• Across five years, Gross Margin topped out at 213.21% in Q3 2022 and bottomed at 58.95% in Q4 2022.
• The 5-year median for Gross Margin is 66.08% (2023), against an average of 74.67%.
• Across the five-year window, Gross Margin surged 14585 bps in 2022 and tumbled 14571 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 58.95% in 2022, then advanced by 8 bps to 63.6% in 2023, then increased by 0 bps to 63.73% in 2024, then retreated by 1 bps to 62.93% in 2025, then rose by 0 bps to 62.93% in 2026.
• Per Business Quant, the three latest TAK Gross Margin figures stand at 62.93% (Q1 2026), 62.93% (Q4 2025), and 66.04% (Q3 2025).